Mahendra Kumar Trivedi1, Sambhu Mondal2, Mayank Gangwar2, Snehasis Jana3. 1. Trivedi Global, Inc., Henderson, NV, USA. 2. Trivedi Science Research Laboratory Pvt. Ltd., Thane, Maharashtra, India. 3. Trivedi Science Research Laboratory Pvt. Ltd., Thane, Maharashtra, India. jana@trivedisrl.com.
Abstract
OBJECTIVE: The study objective was to evaluate the therapeutic effect of cannabidiol (CBD) on a combination of caecal slurry, lipopolysaccharide (LPS), and Escherichia coli (E. coli)-induced systemic inflammatory response syndrome (SIRS) in male Sprague Dawley rats. METHODS: The therapeutic activity was monitored in behavioral tests and inflammatory biomarkers by the enzyme-linked immune sorbent assay (ELISA) method. RESULTS: Behavioral tasks were significantly increased like a tail flick response by 73.84% (p ≤ 0.001), grip strength by 33.56% (p ≤ 0.028), locomotor activity by 20.71% (p = 0.034) in the CBD (60 mg/kg) group compared to disease control (DC) group. Levels of inflammatory serum biomarkers like interleukin-1β (IL-1β), matrix metallopeptidase-9 (MMP-9), IL-6, and tumor necrosis factor-alpha (TNF-α) were significantly decreased by 29.56 (p = 0.041), 71.20 (p ≤ 0.001), 35.05 (p ≤ 0.001), and 75.56% (p = 0.002), respectively, in the CBD-60 compared with DC. Inflammatory cytokines levels, viz. IL-1β, MMP-9, IL-6, and TNF-α, in the liver were significantly (p ≤ 0.001) decreased by 81.01, 40.41, 22.84, and 69.46%, respectively, in CBD-60 to DC. Similarly, levels of inflammatory cytokines such as IL-1β and MMP-9 in the kidney were significantly (p ≤ 0.001) decreased by 80.90 and 43.93%, respectively, in CBD-60 compared to DC. CONCLUSION: Taken together, results suggest that CBD treatment significantly improved behavioral tasks and decreased the level of inflammatory cytokines under SIRS conditions that might provide an opportunity to manage acute and chronic inflammatory disorders.
OBJECTIVE: The study objective was to evaluate the therapeutic effect of cannabidiol (CBD) on a combination of caecal slurry, lipopolysaccharide (LPS), and Escherichia coli (E. coli)-induced systemic inflammatory response syndrome (SIRS) in male Sprague Dawley rats. METHODS: The therapeutic activity was monitored in behavioral tests and inflammatory biomarkers by the enzyme-linked immune sorbent assay (ELISA) method. RESULTS: Behavioral tasks were significantly increased like a tail flick response by 73.84% (p ≤ 0.001), grip strength by 33.56% (p ≤ 0.028), locomotor activity by 20.71% (p = 0.034) in the CBD (60 mg/kg) group compared to disease control (DC) group. Levels of inflammatory serum biomarkers like interleukin-1β (IL-1β), matrix metallopeptidase-9 (MMP-9), IL-6, and tumor necrosis factor-alpha (TNF-α) were significantly decreased by 29.56 (p = 0.041), 71.20 (p ≤ 0.001), 35.05 (p ≤ 0.001), and 75.56% (p = 0.002), respectively, in the CBD-60 compared with DC. Inflammatory cytokines levels, viz. IL-1β, MMP-9, IL-6, and TNF-α, in the liver were significantly (p ≤ 0.001) decreased by 81.01, 40.41, 22.84, and 69.46%, respectively, in CBD-60 to DC. Similarly, levels of inflammatory cytokines such as IL-1β and MMP-9 in the kidney were significantly (p ≤ 0.001) decreased by 80.90 and 43.93%, respectively, in CBD-60 compared to DC. CONCLUSION: Taken together, results suggest that CBD treatment significantly improved behavioral tasks and decreased the level of inflammatory cytokines under SIRS conditions that might provide an opportunity to manage acute and chronic inflammatory disorders.
Authors: Y Avraham; Nc Grigoriadis; T Poutahidis; L Vorobiev; I Magen; Y Ilan; R Mechoulam; Em Berry Journal: Br J Pharmacol Date: 2011-04 Impact factor: 8.739
Authors: D C Hammell; L P Zhang; F Ma; S M Abshire; S L McIlwrath; A L Stinchcomb; K N Westlund Journal: Eur J Pain Date: 2015-10-30 Impact factor: 3.931
Authors: Nicholas A Jones; Sarah E Glyn; Satoshi Akiyama; Thomas D M Hill; Andrew J Hill; Samantha E Weston; Matthew D A Burnett; Yuki Yamasaki; Gary J Stephens; Benjamin J Whalley; Claire M Williams Journal: Seizure Date: 2012-04-19 Impact factor: 3.184
Authors: Jens Baumert; Jie Huang; Barbara McKnight; Maria Sabater-Lleal; Maristella Steri; Audrey Y Chu; Stella Trompet; Lorna M Lopez; Myriam Fornage; Alexander Teumer; Weihong Tang; Alicja R Rudnicka; Anders Mälarstig; Jouke-Jan Hottenga; Maryam Kavousi; Jari Lahti; Toshiko Tanaka; Caroline Hayward; Jennifer E Huffman; Pierre-Emmanuel Morange; Lynda M Rose; Saonli Basu; Ann Rumley; David J Stott; Brendan M Buckley; Anton J M de Craen; Serena Sanna; Marco Masala; Reiner Biffar; Georg Homuth; Angela Silveira; Bengt Sennblad; Anuj Goel; Hugh Watkins; Martina Müller-Nurasyid; Regina Rückerl; Kent Taylor; Ming-Huei Chen; Eco J C de Geus; Albert Hofman; Jacqueline C M Witteman; Moniek P M de Maat; Aarno Palotie; Gail Davies; David S Siscovick; Ivana Kolcic; Sarah H Wild; Jaejoon Song; Wendy L McArdle; Ian Ford; Naveed Sattar; David Schlessinger; Anne Grotevendt; Maria Grazia Franzosi; Thomas Illig; Melanie Waldenberger; Thomas Lumley; Geoffrey H Tofler; Gonneke Willemsen; André G Uitterlinden; Fernando Rivadeneira; Katri Räikkönen; Daniel I Chasman; Aaron R Folsom; Gordon D Lowe; Rudi G J Westendorp; P Eline Slagboom; Francesco Cucca; Henri Wallaschofski; Rona J Strawbridge; Udo Seedorf; Wolfgang Koenig; Joshua C Bis; Kenneth J Mukamal; Jenny van Dongen; Elisabeth Widen; Oscar H Franco; John M Starr; Kiang Liu; Luigi Ferrucci; Ozren Polasek; James F Wilson; Tiphaine Oudot-Mellakh; Harry Campbell; Pau Navarro; Stefania Bandinelli; Johan Eriksson; Dorret I Boomsma; Abbas Dehghan; Robert Clarke; Anders Hamsten; Eric Boerwinkle; J Wouter Jukema; Silvia Naitza; Paul M Ridker; Henry Völzke; Ian J Deary; Alexander P Reiner; David-Alexandre Trégouët; Christopher J O'Donnell; David P Strachan; Annette Peters; Nicholas L Smith Journal: PLoS One Date: 2014-12-31 Impact factor: 3.240
Authors: Karina Genaro; Débora Fabris; Ana L F Arantes; Antônio W Zuardi; José A S Crippa; Wiliam A Prado Journal: Front Pharmacol Date: 2017-06-21 Impact factor: 5.810